APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

RNA-Targeted Small Molecule Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global RNA-Targeted Small Molecule Drugs Market Outlook and Growth Opportunities 2026

Report ID 17423253044 January 2026196 pages

Choose your research edition.

Industry ResearchRNA-Targeted Small Molecule Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-Targeted Small Molecule Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal RNA-Targeted Small Molecule Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-Targeted Small Molecule Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-Targeted Small Molecule Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global RNA-Targeted Small Molecule Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the RNA-Targeted Small Molecule Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the RNA-Targeted Small Molecule Drugs market include Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics and Expansion Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global RNA-Targeted Small Molecule Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNA-Targeted Small Molecule Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNA-Targeted Small Molecule Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global RNA-Targeted Small Molecule Drugs market.

RNA-Targeted Small Molecule Drugs Segment by Company

Roche

Novartis

PTC Therapeutics

Biogen

Accent Therapeutics

Anima Biotech

Arrakis Pharmaceuticals

Epics Therapeutics

Expansion Therapeutics

Gotham Therapeutics

H3 Biomedicine

Ribometrix

Skyhawk Therapeutics

STORM Therapeutics

Twentyeight-Seven Therapeutics

RNA-Targeted Small Molecule Drugs Segment by Type

mRNA Translation Regulation

RNA Splicing Modification

Direct RNA Targeting

Indirect RNA Targeting - Epitranscriptomics

RNA-Targeted Small Molecule Drugs Segment by Application

SMA

Oncology

Lung Fibrosis

Huntington's Disease

Others

RNA-Targeted Small Molecule Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global RNA-Targeted Small Molecule Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the RNA-Targeted Small Molecule Drugs key companies, revenue, market share, and recent developments.

3. To split the RNA-Targeted Small Molecule Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions RNA-Targeted Small Molecule Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify RNA-Targeted Small Molecule Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze RNA-Targeted Small Molecule Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecule Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecule Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecule Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RNA-Targeted Small Molecule Drugs industry.

Chapter 3: Detailed analysis of RNA-Targeted Small Molecule Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of RNA-Targeted Small Molecule Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of RNA-Targeted Small Molecule Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. RNA-Targeted Small Molecule Drugs Industry Trends Table 2. RNA-Targeted Small Molecule Drugs Industry Drivers Table 3. RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges Table 4. RNA-Targeted Small Molecule Drugs Industry Restraints Table 5. Global RNA-Targeted Small Molecule Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global RNA-Targeted Small Molecule Drugs Revenue Share by Company (2021-2026) Table 7. Global RNA-Targeted Small Molecule Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global RNA-Targeted Small Molecule Drugs Key Company Manufacturing Base & Headquarters Table 9. Global RNA-Targeted Small Molecule Drugs Company, Product Type & Application Table 10. Global RNA-Targeted Small Molecule Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global RNA-Targeted Small Molecule Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of mRNA Translation Regulation Table 15. Significant Companies of RNA Splicing Modification Table 16. Significant Companies of Direct RNA Targeting Table 17. Significant Companies of Indirect RNA Targeting - Epitranscriptomics Table 18. Global RNA-Targeted Small Molecule Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global RNA-Targeted Small Molecule Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global RNA-Targeted Small Molecule Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Type (2021-2026) Table 22. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of SMA Table 24. Significant Companies of Oncology Table 25. Significant Companies of Lung Fibrosis Table 26. Significant Companies of Huntington's Disease Table 27. Significant Companies of Others Table 28. Global RNA-Targeted Small Molecule Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global RNA-Targeted Small Molecule Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global RNA-Targeted Small Molecule Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Application (2021-2026) Table 32. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Application (2027-2032) Table 33. Global RNA-Targeted Small Molecule Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global RNA-Targeted Small Molecule Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Region (2021-2026) Table 36. Global RNA-Targeted Small Molecule Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Region (2027-2032) Table 38. Global RNA-Targeted Small Molecule Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global RNA-Targeted Small Molecule Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global RNA-Targeted Small Molecule Drugs Sales Value Market Share by Country (2021-2026) Table 41. Global RNA-Targeted Small Molecule Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global RNA-Targeted Small Molecule Drugs Sales Value Market Share by Country (2027-2032) Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Roche RNA-Targeted Small Molecule Drugs Product Portfolio Table 47. Roche Recent Development Table 48. Novartis Company Information Table 49. Novartis Business Overview Table 50. Novartis RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Novartis RNA-Targeted Small Molecule Drugs Product Portfolio Table 52. Novartis Recent Development Table 53. PTC Therapeutics Company Information Table 54. PTC Therapeutics Business Overview Table 55. PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 57. PTC Therapeutics Recent Development Table 58. Biogen Company Information Table 59. Biogen Business Overview Table 60. Biogen RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Biogen RNA-Targeted Small Molecule Drugs Product Portfolio Table 62. Biogen Recent Development Table 63. Accent Therapeutics Company Information Table 64. Accent Therapeutics Business Overview Table 65. Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 67. Accent Therapeutics Recent Development Table 68. Anima Biotech Company Information Table 69. Anima Biotech Business Overview Table 70. Anima Biotech RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio Table 72. Anima Biotech Recent Development Table 73. Arrakis Pharmaceuticals Company Information Table 74. Arrakis Pharmaceuticals Business Overview Table 75. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio Table 77. Arrakis Pharmaceuticals Recent Development Table 78. Epics Therapeutics Company Information Table 79. Epics Therapeutics Business Overview Table 80. Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 82. Epics Therapeutics Recent Development Table 83. Expansion Therapeutics Company Information Table 84. Expansion Therapeutics Business Overview Table 85. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 87. Expansion Therapeutics Recent Development Table 88. Gotham Therapeutics Company Information Table 89. Gotham Therapeutics Business Overview Table 90. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 92. Gotham Therapeutics Recent Development Table 93. H3 Biomedicine Company Information Table 94. H3 Biomedicine Business Overview Table 95. H3 Biomedicine RNA-Targeted Small Molecule Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio Table 97. H3 Biomedicine Recent Development Table 98. Ribometrix Company Information Table 99. Ribometrix Business Overview Table 100. Ribometrix RNA-Targeted Small Molecule Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio Table 102. Ribometrix Recent Development Table 103. Skyhawk Therapeutics Company Information Table 104. Skyhawk Therapeutics Business Overview Table 105. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 107. Skyhawk Therapeutics Recent Development Table 108. STORM Therapeutics Company Information Table 109. STORM Therapeutics Business Overview Table 110. STORM Therapeutics RNA-Targeted Small Molecule Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 112. STORM Therapeutics Recent Development Table 113. Twentyeight-Seven Therapeutics Company Information Table 114. Twentyeight-Seven Therapeutics Business Overview Table 115. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 117. Twentyeight-Seven Therapeutics Recent Development Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. RNA-Targeted Small Molecule Drugs Product Image Figure 2. Global RNA-Targeted Small Molecule Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global RNA-Targeted Small Molecule Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. mRNA Translation Regulation Image Figure 8. RNA Splicing Modification Image Figure 9. Direct RNA Targeting Image Figure 10. Indirect RNA Targeting - Epitranscriptomics Image Figure 11. Global RNA-Targeted Small Molecule Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global RNA-Targeted Small Molecule Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Type (2021-2032) Figure 14. SMA Image Figure 15. Oncology Image Figure 16. Lung Fibrosis Image Figure 17. Huntington's Disease Image Figure 18. Others Image Figure 19. Global RNA-Targeted Small Molecule Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global RNA-Targeted Small Molecule Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Application (2021-2032) Figure 22. Global RNA-Targeted Small Molecule Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global RNA-Targeted Small Molecule Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America RNA-Targeted Small Molecule Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. North America RNA-Targeted Small Molecule Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe RNA-Targeted Small Molecule Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Europe RNA-Targeted Small Molecule Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific RNA-Targeted Small Molecule Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific RNA-Targeted Small Molecule Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America RNA-Targeted Small Molecule Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. South America RNA-Targeted Small Molecule Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa RNA-Targeted Small Molecule Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa RNA-Targeted Small Molecule Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA Translation Regulation
  • RNA Splicing Modification
  • Direct RNA Targeting
  • Indirect RNA Targeting - Epitranscriptomics
Applications
  • SMA
  • Oncology
  • Lung Fibrosis
  • Huntington's Disease
  • Others
Companies covered
  • Roche
  • Novartis
  • PTC Therapeutics
  • Biogen
  • Accent Therapeutics
  • Anima Biotech
  • Arrakis Pharmaceuticals
  • Epics Therapeutics
  • Expansion Therapeutics
  • Gotham Therapeutics
  • H3 Biomedicine
  • Ribometrix
  • Skyhawk Therapeutics
  • STORM Therapeutics
  • Twentyeight-Seven Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global RNA-Targeted Small Molecule Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 RNA-Targeted Small Molecule Drugs Market Dynamics
  1. 2.1 RNA-Targeted Small Molecule Drugs Industry Trends
  2. 2.2 RNA-Targeted Small Molecule Drugs Industry Drivers
  3. 2.3 RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges
  4. 2.4 RNA-Targeted Small Molecule Drugs Industry Restraints
3 RNA-Targeted Small Molecule Drugs Market by Company
  1. 3.1 Global RNA-Targeted Small Molecule Drugs Company Revenue Ranking in 2025
  2. 3.2 Global RNA-Targeted Small Molecule Drugs Revenue by Company (2021-2026)
  3. 3.3 Global RNA-Targeted Small Molecule Drugs Company Ranking (2024-2026)
  4. 3.4 Global RNA-Targeted Small Molecule Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global RNA-Targeted Small Molecule Drugs Company Product Type and Application
  6. 3.6 Global RNA-Targeted Small Molecule Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global RNA-Targeted Small Molecule Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 RNA-Targeted Small Molecule Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 RNA-Targeted Small Molecule Drugs Market by Type
  1. 4.1 RNA-Targeted Small Molecule Drugs Type Introduction
  2. 4.1.1 mRNA Translation Regulation
  3. 4.1.2 RNA Splicing Modification
  4. 4.1.3 Direct RNA Targeting
  5. 4.1.4 Indirect RNA Targeting - Epitranscriptomics
  6. 4.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Type
  7. 4.2.1 Global RNA-Targeted Small Molecule Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global RNA-Targeted Small Molecule Drugs Sales Value Share by Type (2021-2032)
5 RNA-Targeted Small Molecule Drugs Market by Application
  1. 5.1 RNA-Targeted Small Molecule Drugs Application Introduction
  2. 5.1.1 SMA
  3. 5.1.2 Oncology
  4. 5.1.3 Lung Fibrosis
  5. 5.1.4 Huntington's Disease
  6. 5.1.5 Others
  7. 5.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Application
  8. 5.2.1 Global RNA-Targeted Small Molecule Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Application (2021-2032)
  10. 5.2.3 Global RNA-Targeted Small Molecule Drugs Sales Value Share by Application (2021-2032)
6 RNA-Targeted Small Molecule Drugs Regional Value Analysis
  1. 6.1 Global RNA-Targeted Small Molecule Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global RNA-Targeted Small Molecule Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America RNA-Targeted Small Molecule Drugs Sales Value (2021-2032)
  7. 6.3.2 North America RNA-Targeted Small Molecule Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe RNA-Targeted Small Molecule Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe RNA-Targeted Small Molecule Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific RNA-Targeted Small Molecule Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America RNA-Targeted Small Molecule Drugs Sales Value (2021-2032)
  16. 6.6.2 South America RNA-Targeted Small Molecule Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Sales Value Share by Country, 2025 VS 2032
7 RNA-Targeted Small Molecule Drugs Country-level Value Analysis
  1. 7.1 Global RNA-Targeted Small Molecule Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global RNA-Targeted Small Molecule Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global RNA-Targeted Small Molecule Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt RNA-Targeted Small Molecule Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt RNA-Targeted Small Molecule Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt RNA-Targeted Small Molecule Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Roche
  2. 8.1.1 Roche Company Information
  3. 8.1.2 Roche Business Overview
  4. 8.1.3 Roche RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Roche RNA-Targeted Small Molecule Drugs Product Portfolio
  6. 8.1.5 Roche Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis RNA-Targeted Small Molecule Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 PTC Therapeutics
  14. 8.3.1 PTC Therapeutics Company Information
  15. 8.3.2 PTC Therapeutics Business Overview
  16. 8.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  18. 8.3.5 PTC Therapeutics Recent Developments
  19. 8.4 Biogen
  20. 8.4.1 Biogen Company Information
  21. 8.4.2 Biogen Business Overview
  22. 8.4.3 Biogen RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Biogen RNA-Targeted Small Molecule Drugs Product Portfolio
  24. 8.4.5 Biogen Recent Developments
  25. 8.5 Accent Therapeutics
  26. 8.5.1 Accent Therapeutics Company Information
  27. 8.5.2 Accent Therapeutics Business Overview
  28. 8.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  30. 8.5.5 Accent Therapeutics Recent Developments
  31. 8.6 Anima Biotech
  32. 8.6.1 Anima Biotech Company Information
  33. 8.6.2 Anima Biotech Business Overview
  34. 8.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio
  36. 8.6.5 Anima Biotech Recent Developments
  37. 8.7 Arrakis Pharmaceuticals
  38. 8.7.1 Arrakis Pharmaceuticals Company Information
  39. 8.7.2 Arrakis Pharmaceuticals Business Overview
  40. 8.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio
  42. 8.7.5 Arrakis Pharmaceuticals Recent Developments
  43. 8.8 Epics Therapeutics
  44. 8.8.1 Epics Therapeutics Company Information
  45. 8.8.2 Epics Therapeutics Business Overview
  46. 8.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  48. 8.8.5 Epics Therapeutics Recent Developments
  49. 8.9 Expansion Therapeutics
  50. 8.9.1 Expansion Therapeutics Company Information
  51. 8.9.2 Expansion Therapeutics Business Overview
  52. 8.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  54. 8.9.5 Expansion Therapeutics Recent Developments
  55. 8.10 Gotham Therapeutics
  56. 8.10.1 Gotham Therapeutics Company Information
  57. 8.10.2 Gotham Therapeutics Business Overview
  58. 8.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  60. 8.10.5 Gotham Therapeutics Recent Developments
  61. 8.11 H3 Biomedicine
  62. 8.11.1 H3 Biomedicine Company Information
  63. 8.11.2 H3 Biomedicine Business Overview
  64. 8.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio
  66. 8.11.5 H3 Biomedicine Recent Developments
  67. 8.12 Ribometrix
  68. 8.12.1 Ribometrix Company Information
  69. 8.12.2 Ribometrix Business Overview
  70. 8.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio
  72. 8.12.5 Ribometrix Recent Developments
  73. 8.13 Skyhawk Therapeutics
  74. 8.13.1 Skyhawk Therapeutics Company Information
  75. 8.13.2 Skyhawk Therapeutics Business Overview
  76. 8.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  78. 8.13.5 Skyhawk Therapeutics Recent Developments
  79. 8.14 STORM Therapeutics
  80. 8.14.1 STORM Therapeutics Company Information
  81. 8.14.2 STORM Therapeutics Business Overview
  82. 8.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  84. 8.14.5 STORM Therapeutics Recent Developments
  85. 8.15 Twentyeight-Seven Therapeutics
  86. 8.15.1 Twentyeight-Seven Therapeutics Company Information
  87. 8.15.2 Twentyeight-Seven Therapeutics Business Overview
  88. 8.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  90. 8.15.5 Twentyeight-Seven Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst